Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid.

Philippe Massiot, Pascal Reygagne, Corinne Chagnoleau, Leila Kanoun-Copy, Florence Pouradier, Geneviève Loussouarn, Catherine Queille-Roussel, Hussein Jouni, Delphine Kerob

Journal: European journal of dermatology : EJD 2023;33(S1):13-18

PMID: 37098774

Abstract

INTRODUCTION

Seborrheic dermatitis (SD) is a chronic, relapsing, inflammatory disorder of the head and trunk.

OBJECTIVES

To explore the potential of a 1% Selenium disulphide (SeS2)-based shampoo to prevent relapses of scalp SD (SSD) following corticosteroid/salicylic acid (TCS/SA) treatment.

MATERIALS & METHODS

After a 2-week treatment with TCS/SA, adult patients with moderate-to-severe SSD received either the SeS2-based shampoo or its vehicle for eight weeks in a randomized, double-blinded fashion. Visits took place at baseline, weeks 2, 6 and 10. SSD severity was assessed based on erythema, flakes and pruritus; patients assessed the severity of pruritus. Global investigator and patient satisfaction were assessed at week 10.

RESULTS

Forty-eight adults were included. After four and eight weeks of post TCS/SA maintenance regimen, 8.1% and 16.7% in the SeS2, and 41.7% and 54.2% in the vehicle group relapsed, respectively. First median time-to-relapse in the vehicle group was 56 days; this was not reached for SeS2. After two weeks of TCS/SA, the prevalence of patients with no pruritus was 29.2% in the SeS2 group, and 41.7% in the vehicle group; it increased to 76.2% with SeS2 and to 57.1% with the vehicle at the end of the study. The clinical benefit of treatment with TCS/SCA was maintained in the SeS2 group only. Investigators and patients were highly satisfied with the efficacy of SeS2. Tolerance to SeS2 was excellent, with no reported adverse events.

CONCLUSION

The SeS2-based shampoo significantly reduces the time-to-relapse of moderate-to-severe SSD flares. Its tolerance was excellent, with no reported adverse events.

Address: L'Oréal Research and Innovation, Saint-Ouen, France.; Centre Sabouraud, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.; CPCAD, Hôpital l'Archet Nice, France.; L'Oréal Research and Innovation, Aulnay-sous-Bois, France.; Cosmetic Active International, Levallois-Perret, France.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.